Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany

5 March 2019 - The decision matrix applied by the IQWiG for the quantification of added benefit within the early benefit ...

Read more →

Germany agrees on new pharmaceutical bill

13 February 2019 - On 30 January, the German government has agreed on a draft Act for more safety in ...

Read more →

Erenumab in migraine: indication of a significant added benefit for certain patients

2 February 2019 - As a prophylaxis successful when other drug therapies are exhausted. ...

Read more →

Identifying the need for good practices in health technology assessment-summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA

26 January 2019 - The systematic use of evidence to inform healthcare decisions, particularly health technology assessment, has gained increased recognition.  ...

Read more →

Citizens ask - scientists answer: the IQWiG sets four new topics for HTA reports

23 January 2019 - Citizens, patients and medical experts: selection of topics with a sense of proportion ...

Read more →

Progressive squamous cell carcinoma of the head and neck: pembrolizumab prolongs survival

15 January 2019 - Only a few study participants were treated in compliance with the approval, therefore the extent of ...

Read more →

Rexgenero's lead product REX-001 selected for the EUnetHTA prioritisation list for joint assessments

7 January 2019 - The Prioritisation list consists of just 14 medicinal products that have been identified as being of significant ...

Read more →

EU Health Technology Assessment needs to move up a gear, says pressure group

9 January 2019 - The European Alliance for Personalised Medicine says it may seem to everyone that the whole debate ...

Read more →

Mandatory or voluntary? A sticking point for European HTA

10 January 2019 - The long road to unified European Health Technology Assessment is continuing.  ...

Read more →

2018 in a nutshell: new edition with facts and graphics from the IQWiG

9 January 2019 - The focus of the 33-page brochure is information, overviews and charts on "Health Technology Assessment (HTA) ...

Read more →

Novartis weighs reinsurance tie-up to fund ultra-expensive drugs

17 December 2018 - Could reinsures solve problem of high upfront costs of developing potentially life-saving treatments? ...

Read more →

AMNOG as a learning system: new study on ingenol mebutate in actinic keratosis shows added benefit

3 December 2018 - Advantage over diclofenac in complete clearance of visible lesions / unclear sustainability of treatment effect ...

Read more →

Underuse of innovative medicines in Germany: A justification for government intervention?

6 December 2018 - The German market for innovative medicines is characterised by simultaneous underuse and overuse.  ...

Read more →

German health minister calls for faster adoption of biosimilar drugs

14 November 2018 - Germany’s health minister Jens Spahn has called for faster adoption of cheaper copies of biotech drugs ...

Read more →

Fighting for a streamlined European HTA scheme

6 November 2018 - Anyone wanting a bird’s-eye view of the political operating context for the European pharmaceutical industry need ...

Read more →